{"url_path":"/sec/clrb/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 Exhibits","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1279704/0001104659-26-060678-index.html","accession_number":"0001104659-26-060678","cik":"0001279704","ticker":"CLRB","issuer_name":"Cellectar Biosciences, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1279704/0001104659-26-060678-index.html","primary_entity_key":"0001279704","primary_entity_name":"Cellectar Biosciences, Inc."},"word_count":261,"has_tables":true,"body_markdown":"Item 6. Exhibits\n\n​\n\n \n\n \n\n \n\n \n\n \n\n \n\n**Incorporation by Reference**\n\n**Exhibit**\n**No.**\n\n  ​ ​ ​\n\n**Description**\n\n  ​ ​ ​\n\n**Filed with**\n**this**\n**Form 10-Q**\n\n  ​ ​ ​\n\n**Form**\n\n  ​ ​ ​\n\n**Filing Date**\n\n  ​ ​ ​\n\n**Exhibit**\n**No.**\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n3.1\n\n​\n\n[Amended and Restated By-Laws of Cellectar Biosciences, Inc., effective as of March 11, 2025](https://www.sec.gov/Archives/edgar/data/1279704/000110465925024446/tm259506d1_ex3-1.htm)\n\n​\n\n​\n\n​\n\n8-K\n\n​\n\nMarch 17, 2025\n\n​\n\n3.1\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n31.1\n\n \n\n[Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002](clrb-20260331xex31d1.htm)\n\n \n\nX\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n31.2\n\n \n\n[Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002](clrb-20260331xex31d2.htm)\n\n \n\nX\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n32.1\n\n \n\n[Certification of Chief Executive Officer and Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002](clrb-20260331xex32d1.htm)\n\n \n\nX\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n101\n\n \n\nInteractive Data Files\n\n \n\nX\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n104\n\n​\n\nCover Page Interactive Data File (Embedded within the Inline XBRL document and included in Exhibit).\n\n​\n\nX\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n36\n\n[Table of Contents](#TOC)\n\n**SIGNATURES**\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.\n\n​\n\n \n\n**CELLECTAR BIOSCIENCES, INC.**\n\n \n\n \n\n \n\nDate: May 14, 2026\n\nBy:\n\n*/s/****James V. Caruso*\n\n \n\n \n\nJames V. Caruso\n\n \n\n \n\nPresident and Chief Executive Officer\n\n​\n\n​\n\n(Principal Executive Officer)\n\n​\n\n​\n\n​\n\nDate: May 14, 2026\n\nBy:\n\n*/s/****Chad J. Kolean*\n\n​\n\n​\n\nChad J. Kolean\n\n​\n\n​\n\nChief Financial Officer\n\n​\n\n​\n\n(Principal Financial and Accounting Officer)\n\n​\n\n​\n\n37"}